Public Citizen filed a lawsuit against the Trump administration in the U.S. District Court for the District of Columbia ...

Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...

WASHINGTON (AP) — The U.S. moved a step closer to expanding COVID-19 vaccinations for millions more children as government advisers on Tuesday endorsed kid-size doses of Pfizer’s shots for 5- to ...

Consumer advocacy organization Public Citizen has filed (PDF) a Freedom of Information Act (FOIA) lawsuit against the Department of Health and Human Services (HHS) and the Department of Commerce (DOC) ...

On Tuesday, a key Food and Drug Administration (FDA) panel voted to formally recommend that children as young as 5 be authorized to receive Pfizer's COVID-19 vaccine under emergency use authorization.

While Pfizer gained approval for its drug tafamidis to treat a rare and fatal heart disease, whether insurers and employers will cover the drug’s list price — $225,000 — remains uncertain, according ...

U.S. regulators Tuesday released their first scientific evaluation of Pfizer’s COVID-19 vaccine and confirmed it offers strong protection, setting the stage for the government to green light the ...

Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted a 2028 launch. CEO Albert Bourla explained the pharma's strategy at J.P.

By Maggie Fick and Patrick Wingrove SAN FRANCISCO, Jan 16 (Reuters) - More than half a dozen major drugmakers are ...

The plaintiffs bar has argued that courts can only preempt prescription pharmaceutical state law failure-to-warn claims when the FDA formally rejects a proposed label change. Faced with that exact ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. WASHINGTON (AP) — Pfizer on Tuesday asked ...

Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he ...